The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAccsys Tech Regulatory News (AXS)

Share Price Information for Accsys Tech (AXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 57.00
Bid: 56.60
Ask: 57.80
Change: -0.40 (-0.69%)
Spread: 1.20 (2.12%)
Open: 56.80
High: 57.00
Low: 56.80
Prev. Close: 57.60
AXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 Update

27 Mar 2020 12:03

RNS Number : 8990H
Accsys Technologies PLC
27 March 2020
 

AIM: AXS

Euronext Amsterdam: AXS

 

27 March 2020

 

Accsys Technologies PLC

("Accsys", the "Group" or the "Company")

 

COVID-19 Update

 

Accsys, the fast-growing and eco-friendly company that combines chemistry and technology to create high performance, sustainable wood building products, today announces a trading update in light of COVID-19.

 

People

· During these unprecedented times, the Board of the Company remains committed to the health and well-being of the Group's staff and the wider communities in which it operates. The Company is following government guidelines, has altered working protocols in line with local guidelines, and is continuing to keep these under close review.

 

Operations and cash management

· As a result of initial feedback received concerning the impact of the various government imposed restrictions on our customers and end users, the Company is now expecting a significant reduction in demand in the first quarter of its new financial year. Accordingly, and with a view to optimising cash resources in these uncertain times, the Company is implementing plans to temporarily reduce Accoya® production. However, the impact on expected demand continues to be uncertain and so the Company will retain flexibility to increase production as required and will continue to monitor the situation very closely.

· Tricoya® Hull plant construction progress - some elements of work on site have temporarily stopped due to COVID-19 working guidance issued by the UK government. It remains possible that work will slow further or temporarily be suspended. It is not yet possible to determine the extent of any delay to the project relative to the Company's previous guidance of the plant being operational in the second half of calendar year 2020, however, the Company remains committed to completing the construction project and commencing operations as soon as practically possible.

· Whilst the Company has always maintained a prudent approach to costs, due to the level of heightened uncertainty caused by COVID-19, the Company has identified and is implementing, or considering as necessary, mitigating actions to reduce costs to help offset the effect of expected lower production and sales in order to maximise liquidity and minimise utilisation of cash resources. These actions include:

o A reduction of inventory levels and working capital more generally including to ensure prompt debtor collections;

o A deferral of capex including the Arnhem 4th reactor expansion project, noting that the full capital commitment for this €26m project has not yet been committed to;

o A reduction or deferral of variable pay; in addition the Directors and senior management team have agreed to a temporary 20% reduction in their base salaries effective from 1 April;

o Utilising UK and Netherlands government schemes in respect of payroll costs; and

o A reduction or deferral of non-essential operating costs and new recruitment.

 

· Notwithstanding the above, the Group's longer term projects continue to be progressed and we remain confident about the long term growth prospects for both Accoya® and Tricoya®.

 

Balance sheet and liquidity

· Following Accsys' €46.3million (before expenses) capital raise in December 2019 the Company's balance sheet remains robust.

· The Company's key banking covenant includes ABN facilities which include a minimum EBITDA level for the Netherlands operating entity. The previous expected headroom relating to this covenant was in excess of €10m EBITDA and we therefore do not currently anticipate any issues in meeting this when taking into account the effect of the mitigating actions set out above.

· The Board is therefore confident that the Company has adequate liquidity for the foreseeable future and is focussed on minimising the utilisation of cash resources so as to enable the execution of our longer term capital projects.

 

FY20 trading

· The Group's financial results for the year ending 31 March 2020 remain in-line with the Board's previous expectations, with sales volumes for the full year expected to be approximately 57,500m3.

 

Outlook

· Given the unprecedented levels of uncertainty at this time and the lack of clarity on the duration of the situation, all previous guidance on the Group's future performance is being withdrawn. An update will be provided once there is greater certainty on the trading environment and the impact of COVID-19 on the Group. The Board remains confident in the long-term strong business fundamentals of the Group.

 

 

Rob Harris, CEO, said: "In these incredibly challenging times, we continue to be focussed on ensuring the continued health, safety and well-being of our people. We are all pulling together to manage these extraordinary circumstances in the world and our business. The impact of COVID-19 remains uncertain and as a result we are working with our key stakeholders; employees, customers and suppliers, to ensure we minimise the effect of the disruption. Having completed our capital raise in December 2019, our liquidity is strong and the mitigating actions we are putting in place or continue to plan for are focussed on ensuring we maintain our liquidity, cash resources and future growth optionality. We will continue to review our future costs and capital allocations in this light, and provide certainty where practicable for our dedicated teams to manage."

 

Ends

For further information, please contact:

Accsys Technologies PLC

Robert Harris, CEO

William Rudge, FD

 

via FTI Consulting

Numis Securities Limited -Nominated Adviser and

Joint Broker

Oliver Hardy (NOMAD)

Ben Stoop

 

 

+44 (0) 20 7260 1000

 

 

Investec Bank plc - Joint Broker

 

Carlton Nelson

James Rudd

Alex Wright

 

 

+44 (0) 20 7597 5970

FTI Consulting

Matthew O'Keeffe

Alex Le May

 

+44 (0) 20 3727 1340

 

Off the Grid (The Netherlands)

Frank Neervoort

Yvonne Derkse

 

+31 681 734 236

+31 622 37 96 66

 

Notes to editors:

 

Accsys Technologies PLC (www.accsysplc.com) is a chemical technology group whose primary focus is on the production of Accoya® wood and Tricoya® wood elements, technology licensing via its subsidiary, Titan Wood Limited, which has manufacturing operations in Arnhem, the Netherlands (through its subsidiary Titan Wood B.V.), a European office in London, United Kingdom, an American office in Dallas, Texas (via its subsidiary Titan Wood, Inc.) and technology licensing associated with the acetylation of wood elements via its subsidiary Tricoya Technologies Limited. Any references in this announcement to agreements with Accsys shall mean agreements with either Accsys or its subsidiary entities unless otherwise specified. Accsys Technologies PLC is listed on the London Stock Exchange AIM market and on Euronext Amsterdam, under the symbols 'AXS'. Accsys' operations comprise four principal business units: (i) Accoya® wood production; (ii) building and operating of Tricoya® wood chip acetylation plant in Hull; (iii) technology development, focused on a programme of continuous development of and improvements to the process engineering and operating protocols for the acetylation of solid wood and the development of technology for the acetylation of wood elements; and (iv) the licensing of technology for the production of Accoya® wood and Tricoya® wood elements across the globe.

Tricoya® Consortium In March 2017, Accsys announced the formation of the Tricoya® Consortium to fund, build and operate the Tricoya® plant in Hull, UK. Members of the consortium include BP and the leading manufacturer of sustainable wood-based panels, MEDITE Europe DAC. Tricoya Ventures UK Ltd (TVUK), a subsidiary of Accsys, owns and will operate the Tricoya® plant. TTL exploits all Tricoya® related intellectual property and benefits from any Tricoya® related revenues other than those generated by the Tricoya® plant. The Tricoya® plant is expected to have an initial capacity of 30,000 metric tonnes of Tricoya® chips per annum, enough to produce approximately 40,000m3 of Tricoya® panel products per annum. The Tricoya® plant is expected to reach EBITDA breakeven at approximately 40% design capacity and to take approximately four years to reach full capacity following completion. The location of the Tricoya® plant at Saltend Chemicals Park in Hull allows for expansion when market conditions dictate.

 

Accoya®Wood (www.accoya.com) is produced using Accsys' proprietary patented acetylation technology that effectively converts sustainably grown softwoods and non-durable hardwoods into what is best described as a "high technology wood". Distinguished by its durability, dimensional stability and, perhaps most importantly of all, its reliability (in terms of consistency of both supply and quality), Accoya® wood is particularly suited to exterior applications where performance and appearance are valued. Moreover, the Accoya® wood production process does not compromise the wood's strength or machinability. The combination of dimensional stability, durability and retained strength means that Accoya® wood offers a wealth of new opportunities to architects, designers and specifiers. These benefits result in lower maintenance and total cost of ownership while using a higher sustainable and environmental responsible building material. For a full archive of Accoya® news, visit www.accoya.com/news.

Tricoya® Wood Elements (www.tricoya.com) are produced using Accsys' proprietary technology for the acetylation of wood chips and particles for use in the fabrication of panel products such as medium density fibreboard and particle-board. These products demonstrate enhanced durability and dimensional stability which allow them to be used in a variety of applications that were once limited to solid wood or man-made products. Exploitation of Accsys' proprietary technology relating to Tricoya® Wood Elements is carried out through Tricoya Technologies Limited. Tricoya® Wood Elements are lauded as the first major innovation in the wood composites industry in more than 30 years.

Wood Acetylation is a process which increases the amount of 'acetyl' molecules in wood, thereby changing its physical properties. When carried out to a sufficient level throughout the wood, this process protects wood from rot by making it "inedible" to most micro-organisms and fungi, without - unlike conventional treatments - making it toxic. It also greatly reduces the wood's tendency to swell and shrink, making it less prone to cracking and ensuring that, when painted, it requires dramatically reduced maintenance.

 

'Accsys' and 'AccsysTechnologies'aretrading names of Titan Wood Limited. ACCOYA®, TRICOYA® and the Trimarque Device are registered trademarks owned by Titan Wood Limited ("TWL"), a wholly owned subsidiary of Accsys Technologies PLC, and may not be used or reproduced without written permission from TWL, or in the case of the Tricoya® registered trademark, from Tricoya Technologies Limited, a subsidiary of TWL with exclusive rights to exploit the Tricoya® brand.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDBDGDXGGDDGGR
Date   Source Headline
22nd Jul 20204:44 pmRNSNotifiable Interest - De Engh B.V.
21st Jul 20207:00 amRNSBoard Appointment of Alexander Wessels
15th Jul 20205:59 pmRNSDirector Interests and LTIP Awards
30th Jun 20209:16 amRNSTotal Voting Rights
23rd Jun 20203:58 pmRNSIssue of Shares and Directors' Interests
23rd Jun 20207:14 amRNSPreliminary Results for the year ended 31 March 20
15th Jun 20205:37 pmRNSNotifiable Interest – Teslin
29th May 20205:37 pmRNSTotal Voting Rights
19th May 20207:00 amRNSAppointment of Chairman Designate
12th May 20204:03 pmRNSNotifiable Interest - BGF
7th May 202011:08 amRNSIssuance of Shares
27th Mar 202012:03 pmRNSCOVID-19 Update
4th Mar 20209:36 amRNSNotifiable Interest - De Engh B.V.
28th Feb 202010:26 amRNSTotal Voting Rights
24th Feb 20207:00 amRNSCommercial Agreements with Cerdia Produktions GmbH
17th Feb 20202:18 pmRNSNotifiable Interest - De Engh B.V.
4th Feb 20203:46 pmRNSEmployee Share Participation Plan
27th Dec 20197:00 amRNSNotifiable Interest - Janus Henderson Group
27th Dec 20197:00 amRNSNotifiable Interest - De Engh B.V.
24th Dec 201910:11 amRNSNotifiable Interest - Pershing Securities Limited
23rd Dec 20192:00 pmRNSDirector Dealings
23rd Dec 20197:00 amRNSAdmission and Total Voting Rights
20th Dec 201910:07 amRNSSuccessful Results of General Meeting
20th Dec 20197:00 amRNSResults of Firm Placing and Placing and Open Offer
2nd Dec 201911:14 amRNSDirector Interests and LTIP Awards
28th Nov 20192:16 pmRNSPublication of a Prospectus
28th Nov 20197:01 amRNSInterim Results for six months ending 30 Sept 2019
28th Nov 20197:00 amRNSEquity Raise
18th Oct 20197:00 amRNSAppointment of Chief Executive Officer
30th Sep 20195:17 pmRNSAGM Results
30th Sep 20197:00 amRNSAGM Statement
17th Sep 20196:03 pmRNSNotifiable Interest - Majedie Asset Management
12th Aug 20193:13 pmRNSAGM Notification
2nd Aug 20197:00 amRNSNotifiable Interest - Teslin Participaties
17th Jul 201911:27 amRNSShare purchase by a PDMR
28th Jun 201912:04 pmRNSShare Purchase by PCA
25th Jun 20195:58 pmRNS20190625 - AXS - Directors Interest LTIP
25th Jun 20197:00 amRNSDirectorate Change
25th Jun 20197:00 amRNSPreliminary results for year ended 31 March 2019
30th Apr 20197:00 amRNSAppointment of joint broker
29th Mar 20199:01 amRNSTotal Voting Rights
25th Mar 20197:00 amRNSTrading Update Year Ending March 2019
4th Mar 20195:31 pmRNSShare purchase by a PCA
15th Feb 20197:00 amRNSIssuance of Shares
9th Jan 20197:00 amRNSAgreement with PCG to evaluate Tricoya® plant
21st Dec 20187:03 amRNSResignation of Director
20th Nov 20187:00 amRNSInterim Results for six months ending 30 Sept 2018
24th Sep 20187:00 amRNSAGM Correction Statement
18th Sep 20184:00 pmRNSAGM - Proxy Results
18th Sep 20187:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.